Cargando…
Rocaglamide Prolonged Allograft Survival by Inhibiting Differentiation of Th1/Th17 Cells in Cardiac Transplantation
BACKGROUND: Aglaia (Meliaceae) species are used for treating autoimmune disorders and allergic diseases in Asian countries. Rocaglamide, an extract obtained from Aglaia species, exhibits suppressive effect by regulating the T cell subset balance and cytokine network in cancer. However, whether it ca...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787457/ https://www.ncbi.nlm.nih.gov/pubmed/35087613 http://dx.doi.org/10.1155/2022/2048095 |
_version_ | 1784639367919173632 |
---|---|
author | Dai, Chen Zhou, Xi Wang, Lu Tan, Rumeng Wang, Wei Yang, Bo Zhang, Yucong Shi, Huibo Chen, Dong Wei, Lai Chen, Zhishui |
author_facet | Dai, Chen Zhou, Xi Wang, Lu Tan, Rumeng Wang, Wei Yang, Bo Zhang, Yucong Shi, Huibo Chen, Dong Wei, Lai Chen, Zhishui |
author_sort | Dai, Chen |
collection | PubMed |
description | BACKGROUND: Aglaia (Meliaceae) species are used for treating autoimmune disorders and allergic diseases in Asian countries. Rocaglamide, an extract obtained from Aglaia species, exhibits suppressive effect by regulating the T cell subset balance and cytokine network in cancer. However, whether it can be used in organ transplantation is unknown. In this study, we investigated the antirejection effect and mechanism of action of rocaglamide in a mouse cardiac allograft model. METHODS: Survival studies were performed by administering mice with phosphate-buffered saline (PBS) (n = 6) and rocaglamide (n = 8). Heart grafts were monitored until they stopped beating. After grafting, the mice were sacrificed on day 7 for histological, mixed lymphocyte reaction (MLR), enzyme-linked immunosorbent assay (ELISA), and flow cytometric analyses. RESULTS: Rocaglamide administration significantly prolonged the median survival of the grafts from 7 to 25 days compared with PBS treatment (P < 0.001). On posttransplantation day 7, the rocaglamide-treated group showed a significant decrease in the percentage of Th1 cells (7.9 ± 0.9% vs. 1.58 ± 0.5%, P < 0.001) in the lymph nodes and spleen (8.0 ± 2.5% vs. 2.4 ± 1.3%, P < 0.05). Rocaglamide treatment also significantly inhibited the production of Th17 cells (6.4 ± 1.0% vs. 1.8 ± 0.4%, P < 0.01) in the lymph nodes and spleen (5.9 ± 0.3% vs. 2.9 ± 0.8%, P < 0.01). Furthermore, the prolonged survival of the grafts was associated with a significant decrease in IFN-γ and IL-17 levels. Our results also showed that NF-AT activation was inhibited by rocaglamide, which also induced p38 and Jun N-terminal kinase (JNK) phosphorylation in Jurkat T cells. Furthermore, by using inhibitors that suppressed p38 and JNK phosphorylation, rocaglamide-mediated reduction in NF-AT protein levels was prevented. CONCLUSION: We identified a new immunoregulatory property of rocaglamide, wherein it was found to regulate oxidative stress response and reduce inflammatory cell infiltration and organ injury, which have been associated with the inhibition of NF-AT activation in T cells. |
format | Online Article Text |
id | pubmed-8787457 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-87874572022-01-26 Rocaglamide Prolonged Allograft Survival by Inhibiting Differentiation of Th1/Th17 Cells in Cardiac Transplantation Dai, Chen Zhou, Xi Wang, Lu Tan, Rumeng Wang, Wei Yang, Bo Zhang, Yucong Shi, Huibo Chen, Dong Wei, Lai Chen, Zhishui Oxid Med Cell Longev Research Article BACKGROUND: Aglaia (Meliaceae) species are used for treating autoimmune disorders and allergic diseases in Asian countries. Rocaglamide, an extract obtained from Aglaia species, exhibits suppressive effect by regulating the T cell subset balance and cytokine network in cancer. However, whether it can be used in organ transplantation is unknown. In this study, we investigated the antirejection effect and mechanism of action of rocaglamide in a mouse cardiac allograft model. METHODS: Survival studies were performed by administering mice with phosphate-buffered saline (PBS) (n = 6) and rocaglamide (n = 8). Heart grafts were monitored until they stopped beating. After grafting, the mice were sacrificed on day 7 for histological, mixed lymphocyte reaction (MLR), enzyme-linked immunosorbent assay (ELISA), and flow cytometric analyses. RESULTS: Rocaglamide administration significantly prolonged the median survival of the grafts from 7 to 25 days compared with PBS treatment (P < 0.001). On posttransplantation day 7, the rocaglamide-treated group showed a significant decrease in the percentage of Th1 cells (7.9 ± 0.9% vs. 1.58 ± 0.5%, P < 0.001) in the lymph nodes and spleen (8.0 ± 2.5% vs. 2.4 ± 1.3%, P < 0.05). Rocaglamide treatment also significantly inhibited the production of Th17 cells (6.4 ± 1.0% vs. 1.8 ± 0.4%, P < 0.01) in the lymph nodes and spleen (5.9 ± 0.3% vs. 2.9 ± 0.8%, P < 0.01). Furthermore, the prolonged survival of the grafts was associated with a significant decrease in IFN-γ and IL-17 levels. Our results also showed that NF-AT activation was inhibited by rocaglamide, which also induced p38 and Jun N-terminal kinase (JNK) phosphorylation in Jurkat T cells. Furthermore, by using inhibitors that suppressed p38 and JNK phosphorylation, rocaglamide-mediated reduction in NF-AT protein levels was prevented. CONCLUSION: We identified a new immunoregulatory property of rocaglamide, wherein it was found to regulate oxidative stress response and reduce inflammatory cell infiltration and organ injury, which have been associated with the inhibition of NF-AT activation in T cells. Hindawi 2022-01-17 /pmc/articles/PMC8787457/ /pubmed/35087613 http://dx.doi.org/10.1155/2022/2048095 Text en Copyright © 2022 Chen Dai et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Dai, Chen Zhou, Xi Wang, Lu Tan, Rumeng Wang, Wei Yang, Bo Zhang, Yucong Shi, Huibo Chen, Dong Wei, Lai Chen, Zhishui Rocaglamide Prolonged Allograft Survival by Inhibiting Differentiation of Th1/Th17 Cells in Cardiac Transplantation |
title | Rocaglamide Prolonged Allograft Survival by Inhibiting Differentiation of Th1/Th17 Cells in Cardiac Transplantation |
title_full | Rocaglamide Prolonged Allograft Survival by Inhibiting Differentiation of Th1/Th17 Cells in Cardiac Transplantation |
title_fullStr | Rocaglamide Prolonged Allograft Survival by Inhibiting Differentiation of Th1/Th17 Cells in Cardiac Transplantation |
title_full_unstemmed | Rocaglamide Prolonged Allograft Survival by Inhibiting Differentiation of Th1/Th17 Cells in Cardiac Transplantation |
title_short | Rocaglamide Prolonged Allograft Survival by Inhibiting Differentiation of Th1/Th17 Cells in Cardiac Transplantation |
title_sort | rocaglamide prolonged allograft survival by inhibiting differentiation of th1/th17 cells in cardiac transplantation |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787457/ https://www.ncbi.nlm.nih.gov/pubmed/35087613 http://dx.doi.org/10.1155/2022/2048095 |
work_keys_str_mv | AT daichen rocaglamideprolongedallograftsurvivalbyinhibitingdifferentiationofth1th17cellsincardiactransplantation AT zhouxi rocaglamideprolongedallograftsurvivalbyinhibitingdifferentiationofth1th17cellsincardiactransplantation AT wanglu rocaglamideprolongedallograftsurvivalbyinhibitingdifferentiationofth1th17cellsincardiactransplantation AT tanrumeng rocaglamideprolongedallograftsurvivalbyinhibitingdifferentiationofth1th17cellsincardiactransplantation AT wangwei rocaglamideprolongedallograftsurvivalbyinhibitingdifferentiationofth1th17cellsincardiactransplantation AT yangbo rocaglamideprolongedallograftsurvivalbyinhibitingdifferentiationofth1th17cellsincardiactransplantation AT zhangyucong rocaglamideprolongedallograftsurvivalbyinhibitingdifferentiationofth1th17cellsincardiactransplantation AT shihuibo rocaglamideprolongedallograftsurvivalbyinhibitingdifferentiationofth1th17cellsincardiactransplantation AT chendong rocaglamideprolongedallograftsurvivalbyinhibitingdifferentiationofth1th17cellsincardiactransplantation AT weilai rocaglamideprolongedallograftsurvivalbyinhibitingdifferentiationofth1th17cellsincardiactransplantation AT chenzhishui rocaglamideprolongedallograftsurvivalbyinhibitingdifferentiationofth1th17cellsincardiactransplantation |